Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414141 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety/Tolerability of Grass MATA MPL
A Phase 3 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,028
- Enrollment target
NCT00414141: Completed Phase 3 study, sponsored by Allergy Therapeutics.
NCT00414141 is a Phase 3 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 1,028 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00414141, a Phase 3 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,028 participants
- Enrollment target
Study Summary
Grass MATA MPL has been developed by Allergy Therapeutics (UK) Ltd. to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting grass pollens causing rhinitis and/or conjunctivitis with or without mild to moderate asthma bronchiale. The purpose of this study is to compare the efficacy of Grass MATA MPL versus placebo in grass-allergic subjects following 4 subcutaneous injections of study medication administered before the start of the 2007 grass pollen season.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Grass MATA MPL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,028 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00414141 record still lists
NCT00414141 is an interventional study that assigns participants to a tested intervention. Its 1,028 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00414141 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00414141 about?
NCT00414141 is a clinical study titled "Efficacy and Safety/Tolerability of Grass MATA MPL". Grass MATA MPL has been developed by Allergy Therapeutics (UK) Ltd. to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting grass pollens causing rhinitis and/or conjunctivitis with or without mild to moderate asthma bronchiale. The purpose o...
What is the current status of trial NCT00414141?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,028 participants. The study started on 2006-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00414141?
The interventions under investigation include: Placebo (BIOLOGICAL), Grass MATA MPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00414141?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00414141's enrollment target sits among peer trials
1,028 288th of 2000 higher than 1,713 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia